Industry Trend

Site Sections

Menu








© 2023. All Rights reserved.

Overview for ASTELLAS PHARMA

All Data per May 25, 2023

Industry:

Drug Manufacturers—General

Last Close:

2,319.50 JPY

Expected Dividend:

2.85 %

Payoffs per Year:

2
Business Summary
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; and research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

Competitors View

Ordering

PFIZER

USA		 0.89 3.74%
4.36%		 6.07% 4.49% 1.0 0.61
-43.29%		 46.05 16.02% 48.64 1.0

ABBVIE

USA		 1.02 3.5%
4.3%		 10.17% 5.07% 1.0 3.15
-14.88%		 42.79 13.02% 12.45 2.0

ASTRAZENECA

GBR		 1.06 3.6%
2.11%		 5.97% 4.3% 0.5 16.21
-3.86%		 67.14 17.71% 38.41 3.0

SANOFI

FRA		 1.11 3.8%
3.58%		 1.59% 3.73% 1.0 0.88
-12.18%		 49.68 12.1% 59.3 4.0

CHUGAI PHARMACEUTICAL

JPN		 0.98 1.38%
2.08%		 16.13% 2.65% 1.0 3.06
-38.8%		 42.96 15.38% 77.21 5.0

MERCK & CO.

USA		 1.09 3.4%
2.67%		 5.29% 3.94% 1.0 3.67
-11.68%		 47.47 8.91% 42.19 6.0

BRISTOL-MYERS SQUIBB

USA		 0.95 2.6%
4.47%		 2.48% 2.66% 1.0 0.53
-24.44%		 34.16 17.14% 32.14 7.0

ASTELLAS PHARMA

JPN
 1.01 2.35%
2.85%		 19.78% 5.38% 1.0 1.47
-19.06%		 31.03 -2.41% 62.61 8.0

ELI LILLY AND COMPANY

USA		 1.1 2.36%
1.06%		 14.8% 4.25% 1.0 11.83
-12.71%		 45.05 7.83% 21.77 9.0

AMGEN

USA		 0.95 2.75%
3.93%		 10.11% 3.97% 1.0 1.83
-17.4%		 38.25 -3.13% 5.62 10.0

DAIICHI SANKYO

JPN		 1.07 2.05%
0.7%		 6.06% 2.46% 1.0 10.21
-17.26%		 41.99 11.62% 60.81 11.0

KYOWA HAKKO KOGYO

JPN		 0.95 1.65%
1.91%		 8.0% 2.16% 1.0 3.07
-15.61%		 44.19 3.67% 81.16 12.0

OTSUKA HOLDINGS CO., LTD.

JPN		 1.01 2.16%
1.93%		 0.0% 1.98% 1.0 0.44
-14.62%		 29.23 12.66% 72.92 13.0

ROCHE

CHE		 0.92 3.1%
3.27%		 1.69% 3.06% 1.0 0.55
-23.37%		 40.4 0.0% 36.32 14.0

GILEAD SCIENCES

USA		 1.04 3.5%
3.89%		 3.61% 3.76% 0.5 0.24
-42.43%		 36.76 3.95% 33.57 15.0

JOHNSON & JOHNSON

USA		 0.96 2.69%
3.05%		 5.9% 3.2% 1.0 0.19
-12.62%		 46.37 -0.95% 40.99 16.0

BAYER

GER		 1.06 2.96%
3.68%		 0.81% 2.81% 0.5 -0.3
-58.76%		 37.48 -6.72% 31.17 17.0

GLAXOSMITHKLINE

GBR		 1.02 6.49%
2.62%		 0.0% 5.95% -1.0 0.02
-24.56%		 47.0 -2.84% 16.79 18.0

GRIFOLS SA

ESP		 0.91 1.1%
0.0%		 -53.18% 0.2% -0.5 -0.11
-65.73%		 32.66 2.01% 38.04 19.0

Information for ASTELLAS PHARMA

Yield Triangle

Dividend & Close

Dividend Close Div.-Yield
Year
2023 66.00 2,319.50 2.85
2022 55.00 2,006.50 2.74
2021 46.00 1,870.50 2.46
2020 41.00 1,594.00 2.57
2019 39.00 1,870.00 2.09
2018 37.00 1,401.50 2.64
2017 35.00 1,437.00 2.44
2016 33.00 1,623.50 2.03

Fundamentals

Chart